Medical benefit pharmaceutical policies for providers
See the latest updates to our medical benefit pharmaceutical policies.
MBP 59.0 White Blood Cell Stimulating Factors
White blood cell stimulating factors such as granulocyte colony stimulating factors (G-CSF) [e.g., Neupogen (filgrastim), Neulasta (pegfilgrastim), Nivestym (filgrastim-aafi), Releuko (filgrastim-ayow), Nyvepria (pegfilgrastim-apgf), Fulphila (pegfilgrastim-jmdb), Udenyca (pegfilgrastim-cbqv), Ziextenzo (pegfilgrastim-bmez), Zarxio (pegfilgrastim-sndz), and Granix (tbo-filgrastim)] and granulocyte-macrophage colony stimulating factor (GM-CSF) [e.g., Leukine (sargramostim)] are synthetic stimulants and anti-neutropenic agents administered to decrease the incidence and/or severity of infection associated with drug-related myelosuppression and to assist recovery of hematopoietic function in neutropenia.
Learn more about Geisinger Health Plan.
Log in to NaviNet to access and view prior authorization information.
Clinical guidelines offer providers consistent and appropriate guidance for diagnosis and treatment of specific conditions or diseases.
Terms and conditions
View GHP’s terms and conditions.
Questions? Contact us
If you have questions or need more information, contact Geisinger Health Plan.